Bayer

MediSapiens, Bayer HealthCare collaborate in oncology

Tuesday, October 11, 2011 01:01 PM

MediSapiens and Bayer HealthCare Pharmaceuticals have agreed to develop a platform for genomics data management and analysis in oncology.

More... »

Bayer’s phase III prostate cancer trial meets primary endpoint

Tuesday, September 27, 2011 11:39 AM

Bayer HealthCare Pharmaceuticals has reported that the investigational drug radium-223 chloride showed positive data in the phase III ALSYMPCA (ALpharadin in SYMptomatic prostate cancer) trial. The study met its primary endpoint by significantly improving overall survival by 44% in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. All of the main secondary efficacy endpoints analyzed to date were met, including delay in skeletal-related events (SREs).

More... »

Bayer’s Radium-223 granted Fast Track Designation

Tuesday, August 23, 2011 12:58 PM

Bayer HealthCare Pharmaceuticals’ investigational compound radium-223 chloride, which is exclusively licensed from Algeta ASA, has been granted Fast Track designation by the FDA for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with bone metastases.

More... »

The CenterWatch Monthly, June 2011

Wednesday, June 1, 2011 01:51 PM

Sites rate Novo Nordisk, Roche, Amgen on top

More... »

Bayer to cut 540 jobs

Friday, May 27, 2011 12:23 PM

Bayer HealthCare is ending production of its multiple sclerosis drug Betaseron in Emeryville, Calif. and taking it to Germany, according to Fierce Pharma. The production move will cut about 540 jobs.  Betaseron will be produced under a contract with Boehringer Ingelheim.

More... »

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »

Regeneron/Bayer reveal positive results for CRVO study

Friday, April 29, 2011 11:22 AM

Regeneron Pharmaceuticals and Bayer HealthCare reveal positive results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the phase III GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). 

More... »

Regulus Therapeutics appoints Neil W. Gibson as CSO

Monday, April 18, 2011 01:09 PM

Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

More... »

Manning, Chang new appointments at Aileron

Tuesday, April 12, 2011 12:35 PM

CAMBRIDGE, Mass.-based Aileron Therapeutics, a biopharmaceutical company that has developed a new class of drugs called stapled peptides, has appointed Anthony M. Manning, Ph.D., to senior vice president of research and preclinical development and Yong S. Chang, Ph.D., to head of biology.

More... »

Bayer will consolidate in New Jersey

Tuesday, April 5, 2011 02:41 PM

Bayer HealthCare has selected New Jersey as the place to consolidate its East-Coast business site.

More... »